AU2019389025B2 - TYK2 inhibitors and uses thereof - Google Patents

TYK2 inhibitors and uses thereof

Info

Publication number
AU2019389025B2
AU2019389025B2 AU2019389025A AU2019389025A AU2019389025B2 AU 2019389025 B2 AU2019389025 B2 AU 2019389025B2 AU 2019389025 A AU2019389025 A AU 2019389025A AU 2019389025 A AU2019389025 A AU 2019389025A AU 2019389025 B2 AU2019389025 B2 AU 2019389025B2
Authority
AU
Australia
Prior art keywords
oxygen
sulfur
nitrogen
membered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019389025A
Other languages
English (en)
Other versions
AU2019389025A1 (en
Inventor
Jeremy Robert Greenwood
Craig E. Masse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2019389025A1 publication Critical patent/AU2019389025A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: NIMBUS LAKSHMI, INC.
Application granted granted Critical
Publication of AU2019389025B2 publication Critical patent/AU2019389025B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019389025A 2018-11-30 2019-11-27 TYK2 inhibitors and uses thereof Active AU2019389025B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773620P 2018-11-30 2018-11-30
US62/773,620 2018-11-30
PCT/US2019/063510 WO2020112937A1 (en) 2018-11-30 2019-11-27 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2019389025A1 AU2019389025A1 (en) 2021-06-17
AU2019389025B2 true AU2019389025B2 (en) 2025-07-24

Family

ID=70848642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019389025A Active AU2019389025B2 (en) 2018-11-30 2019-11-27 TYK2 inhibitors and uses thereof

Country Status (8)

Country Link
US (2) US11053241B2 (https=)
EP (1) EP3886843A4 (https=)
JP (3) JP7530360B2 (https=)
CN (1) CN113271938A (https=)
AU (1) AU2019389025B2 (https=)
CA (1) CA3120866A1 (https=)
IL (1) IL283409B1 (https=)
WO (1) WO2020112937A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
JP2024501507A (ja) * 2020-12-25 2024-01-12 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド ケトヘキソキナーゼ阻害剤及びその用途
CA3213816A1 (en) 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
TW202425965A (zh) * 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
CN115974751A (zh) * 2022-12-13 2023-04-18 山东能源集团新材料有限公司 一种吡拉西坦制备方法及系统
CN120752237A (zh) * 2022-12-22 2025-10-03 普罗泰克特治疗有限公司 吡咯并吡啶和吡咯并哒嗪类化合物及其作为pkr抑制剂的用途
WO2025010294A2 (en) * 2023-07-03 2025-01-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
US11878978B1 (en) 2023-09-06 2024-01-23 King Faisal University Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
CN117342955A (zh) * 2023-10-08 2024-01-05 盐城师范学院 一种制备4’-甲基-联苯-2-胺的方法
WO2025222103A1 (en) * 2024-04-19 2025-10-23 Raythera, Inc. Stat6 modulators and methods of uses thereof
WO2025264818A1 (en) * 2024-06-20 2025-12-26 Raythera, Inc. Stat6 modulators and methods of uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071794A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
CN1264381A (zh) * 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
KR20070034049A (ko) * 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
KR101764575B1 (ko) * 2004-07-28 2017-08-03 다케다 야쿠힌 고교 가부시키가이샤 피롤로〔2,3-ｃ〕피리딘 화합물, 그 제조 방법 및 용도
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
PL3137470T3 (pl) 2014-05-01 2021-10-11 Novartis Ag Związki i kompozycje jako agonisty receptora toll-like 7
EP4198031A1 (en) * 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071794A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2026053668A (ja) 2026-03-25
JP2022509260A (ja) 2022-01-20
AU2019389025A1 (en) 2021-06-17
JP7530360B2 (ja) 2024-08-07
US11053241B2 (en) 2021-07-06
IL283409B1 (en) 2026-03-01
WO2020112937A1 (en) 2020-06-04
IL283409A (en) 2021-07-29
EP3886843A4 (en) 2022-08-31
US20200172540A1 (en) 2020-06-04
JP2024160253A (ja) 2024-11-13
US11834449B2 (en) 2023-12-05
CN113271938A (zh) 2021-08-17
US20220106306A1 (en) 2022-04-07
EP3886843A1 (en) 2021-10-06
CA3120866A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
AU2019389025B2 (en) TYK2 inhibitors and uses thereof
AU2023237060B2 (en) TYK2 inhibitors and uses thereof
EP3262049B1 (en) Tyk2 inhibitors and uses thereof
US12338242B2 (en) TYK2 inhibitors and uses thereof
AU2019360941A1 (en) TYK2 inhibitors and uses thereof
HK40055822B (en) Tyk2 inhibitors and uses thereof
HK40055822A (en) Tyk2 inhibitors and uses thereof
HK40009936B (en) Tyk2 inhibitors and uses thereof
HK40009936A (en) Tyk2 inhibitors and uses thereof
HK1248690B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): NIMBUS LAKSHMI, INC.

FGA Letters patent sealed or granted (standard patent)